---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-352750"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:33:38.247381+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO

## Summary
- Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.
- R&D expenses fell to $4.7M from $116.9M; G&A increased to $8.9M from $2.1M.
- Completed IPO raising $334.5M gross ($311.1M net); cash position sufficient through 2023.
- Initiated PK study of mavacamten and Phase 2a trial of infigratinib in China.
- Appointed Jesse Wu and Susan Silbermann to board; new chief scientific advisor and China GM.

## SEC filing metadata
- accession: 0001193125-21-352750
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/0001193125-21-352750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/d455505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-352750
- JSON: https://secwatch.observer/filing/0001193125-21-352750.json
- Plain text: https://secwatch.observer/filing/0001193125-21-352750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.